CVE-2026-21974: Oracle Life Sciences Information Disclosure

CVE-2026-21974 Overview

CVE-2026-21974 is an information exposure vulnerability affecting the Oracle Life Sciences Central Designer product within Oracle Health Sciences Applications. The vulnerability exists in the Platform component and allows unauthenticated attackers to gain unauthorized read access to a subset of accessible data through network-based HTTP requests.

This vulnerability is classified under CWE-200 (Exposure of Sensitive Information to an Unauthorized Actor), which indicates that the application fails to properly restrict access to sensitive information, potentially exposing confidential data to unauthorized parties.

Critical Impact

Unauthenticated attackers with network access can exploit this vulnerability via HTTP to access sensitive data without any user interaction required.

Affected Products

• Oracle Life Sciences Central Designer version 7.0.1.0
• Oracle Health Sciences Applications (Platform component)

Discovery Timeline

• January 20, 2026 - CVE-2026-21974 published to NVD
• January 21, 2026 - Last updated in NVD database

Technical Details for CVE-2026-21974

Vulnerability Analysis

This vulnerability stems from inadequate access control mechanisms within the Platform component of Oracle Life Sciences Central Designer. The flaw allows remote attackers to bypass authentication requirements and directly access protected data endpoints over HTTP.

The vulnerability is characterized by its ease of exploitation—no authentication credentials or user interaction are required. An attacker simply needs network connectivity to the vulnerable application to initiate an attack. The impact is limited to confidentiality; the vulnerability does not allow modification or destruction of data.

Healthcare and life sciences applications like Central Designer often contain sensitive clinical trial data, patient information, and proprietary research data. Unauthorized access to even a subset of this data could have significant regulatory and privacy implications.

Root Cause

The root cause is an information exposure vulnerability (CWE-200) in the Platform component. The application fails to properly authenticate requests to certain data endpoints, allowing unauthenticated users to retrieve sensitive information that should be protected.

This type of vulnerability typically occurs when:

• Access control checks are missing on specific API endpoints or data resources
• Authentication mechanisms are improperly implemented or bypassed
• Sensitive data is exposed through predictable URL patterns or insecure direct object references

Attack Vector

The attack is conducted remotely over the network via HTTP requests. An attacker can exploit this vulnerability by:

1. Identifying the vulnerable Oracle Life Sciences Central Designer instance on the network
2. Crafting HTTP requests to target unprotected data endpoints in the Platform component
3. Extracting sensitive data from the responses without providing authentication credentials

The vulnerability requires no privileges, no user interaction, and has low attack complexity, making it readily exploitable by any attacker with network access to the vulnerable system.

Detection Methods for CVE-2026-21974

Indicators of Compromise

• Unusual or unauthorized HTTP requests to Oracle Life Sciences Central Designer endpoints from unknown IP addresses
• Increased volume of data access requests without corresponding authenticated sessions
• Access log entries showing requests to sensitive data endpoints without authentication tokens
• Anomalous patterns of data retrieval from external or unexpected network sources

Detection Strategies

• Monitor web server access logs for requests to the Platform component endpoints that lack authentication headers
• Implement network traffic analysis to identify unusual data exfiltration patterns from the Central Designer application
• Deploy web application firewalls (WAF) with rules to detect and alert on suspicious access patterns
• Configure SIEM rules to correlate unauthenticated access attempts with data retrieval events

Monitoring Recommendations

• Enable detailed logging for all HTTP requests to Oracle Life Sciences Central Designer
• Establish baseline metrics for normal data access patterns and alert on deviations
• Monitor for reconnaissance activities targeting Oracle Health Sciences Applications infrastructure
• Implement real-time alerting for access attempts from untrusted network segments

How to Mitigate CVE-2026-21974

Immediate Actions Required

• Apply the security patches provided in the Oracle Critical Patch Update (CPU) January 2026
• Restrict network access to Oracle Life Sciences Central Designer to authorized users and IP ranges only
• Implement additional authentication controls at the network perimeter if immediate patching is not possible
• Audit access logs to determine if the vulnerability has been exploited prior to patching

Patch Information

Oracle has addressed this vulnerability in the January 2026 Critical Patch Update. Organizations running Oracle Life Sciences Central Designer version 7.0.1.0 should apply the relevant patches immediately.

For detailed patch information and download links, refer to the Oracle Security Alert January 2026.

Workarounds

• Implement network segmentation to isolate Oracle Life Sciences Central Designer from untrusted networks
• Deploy a web application firewall (WAF) to filter and monitor HTTP traffic to the application
• Enforce VPN or zero-trust network access requirements for all connections to the vulnerable system
• Disable or restrict access to the affected Platform component functionality until patching is complete

# Example: Network access restriction using iptables
# Restrict access to Oracle Life Sciences Central Designer to trusted networks only
iptables -A INPUT -p tcp --dport 80 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 443 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 80 -j DROP
iptables -A INPUT -p tcp --dport 443 -j DROP